Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
The company posted Q2 revenues of $536.6 million, up from $494.7 million in Q2 2015 and beating the average Wall Street estimate of $523.4 million.
Under new ownership after being acquired by GHO Capital, the company will consider expanding its business through acquisitions and moving into new geographies.
The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.
At the National Center for Quantitative Biology of Complex Systems, scientists hope mass spec will drive new biological questions and vice versa.
In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.
At Nature, John Wilbanks and Eric Topol call for openness in health data.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.